Express News | Citius Pharmaceuticals Inc - Co Is Guarantor of Obligations of Citius Oncology, Inc Under Asset Purchase Agreement
Express News | Citius Pharmaceuticals - DR. Reddy's Agreed to Partial Deferral Without Penalty of Milestone Payment by Citius Oncology Inc
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Express News | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Lymphir™ (Denileukin Diftitox-Cxdl) Added to National Comprehensive Cancer Network (Nccn) Clinical Practice Guidelines in Oncology
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
EF Hutton Maintains Buy on Citius Pharma, Maintains $6 Price Target
Citius Pharma Analyst Ratings
Buy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product Data
Citius Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Maxim Group Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
Maxim Group analyst Michael Okunewitch maintains $Citius Pharmaceuticals(CTXR.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate
Citius Pharmaceuticals Completes Merger of Oncology Subsidiary With Blank Check Firm TenX Keane
Citius Pharmaceuticals GAAP EPS of -$0.06 Misses by $0.01
Express News | Citius Pharmaceuticals Q3 Basic EPS USD -0.06
Express News | Citius Pharmaceuticals Q3 Net Income USD -10.6 Million
Express News | Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update
10-Q: Q3 2024 Earnings Report
Citius Pharmaceuticals Completes Merger of Subsidiary With TenX Keane to Form Citius Oncology, Inc.
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Catalyst Watch: Eyes on Walmart Earnings, the July CPI Print, and 13F Filings